How to Buy Insmed Stock
Insmed Inc
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases.
Insmed stock last closed at $72.00, up 0.84% from the previous day, and has increased 191.26% in one year. It has overperformed other stocks in the Biotechnology industry by 2.68 percentage points. Insmed stock is currently +228.47% from its 52-week low of $21.92, and -15.2% from its 52-week high of $84.91.
As of Apr 30, 2025, there are 181M shares of INSM outstanding. The market cap of INSM is $13.03B. In the past 24 hours, 1.49M INSM shares were traded.
How to Buy Insmed Stock
Wondering how to invest in Insmed stock? Here's how.
- Figure out where to buy Insmed stock: You need to pick a stock brokerage, but don't worry - we've researched dozens of stock brokerages and apps to help you choose where to buy Insmed stock.
- Sign up for your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Choose your method of payment and add your information.
- Analyze Insmed stock: The Insmed ticker symbol is INSM. Is Insmed stock a good investment? Should you buy shares of INSM? How do INSM's underlying business fundamentals look? Do top analysts think Insmed is a good buy? Why has INSM's stock price moved recently? (Hint: Our stock market analysis website can help you understand if INSM is a good stock to buy).
- Place your INSM buy order: Decide if you will purchase INSM shares at the current market price or use a limit order to purchase INSM shares at a given price.
- Get updates on your investment in INSM: Create a watchlist to key updates about your investment in Insmed stock.
Step 1: Figure out where to buy Insmed stock
You will need a brokerage account to access the NASDAQ market and buy INSM stock.
Our favorite brokerage: eToro
Based on our experience, eToro is the best brokerage. Here's why:
- You can invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world markets: From Technology to Real Estate, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading stock exchanges.
- Social investing: eToro has a community of more than 20 million users globally. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've selected the best brokerage, it's time to fill out some personal details so you can buy INSM stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to open a new trading account.
- Send your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have filled out your info on the best stock broker app, your next step is to transfer the money for your investment:
Watch the video below for more details transferring funds into your brokerage account.
Step 4: Analyze Insmed stock
Once you have identified the best place to buy Insmed stock, it's very important to evaluate their stock prior to buying, so you actually comprehend the risk as well as the upside.
Insmed shares at a glance
INSM Due Diligence Checks
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on INSM's stock page.
Is INSM stock undervalued or overvalued?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge INSM's fair value.
Using relative valuations metrics:
- INSM could be overvalued based on its P/B ratio of 45.67x, relative to Biotechnology industry P/B ratio of 4.45x
You can do more valuation analysis on INSM's stock here.
Is INSM a healthy company?
Passed Financial Due Diligence Checks:
- INSM has $1.43B in cash and short term investments. This is enough to cover its annual cash burn of $705.81M.
- There are more short-term assets than short-term liabilities on the INSM balance sheet.
- There are more short-term assets than long-term liabilities on the INSM balance sheet.
- INSM has cash burn of 705805000. It has enough cash and short-term investments to cover this for at least one year.
Failed Financial Due Diligence Checks:
- INSM has a relatively high debt to equity ratio of 6.1.
- INSM profit margin has gone down from -245.6% to -251.2% in the past year.
- Total INSM debt is higher than 5 years ago, relative to shareholder equity.
Is it a good time to buy Insmed stock, according to analysts?
Out of 10 Equities analysts who give recommendations on INSM, the consensus analyst rating on INSM is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
Latest INSM Analyst Upgrades/Downgrades
Nicole Germino, a top 29% analyst from Truist Securities maintains INSM with a strong buy rating and raises their INSM price target from $105.00 to $108.00, on Feb 21, 2025.
Truist Securities's Nicole Germino raised their price target on Insmed (NASDAQ: INSM) by 2.9% from $105 to $108 on 2025/02/21. The analyst maintained their Strong Buy rating on the stock.
Insmed reported its Q4 and FY 2024 earnings.
No surprises were revealed on the Q4 earnings call given the pre-announced Arikayce FY 2024 revenues and FY 2025 guidance, Germino told readers.
Management reaffirmed its commitment to preparing for a successful commercial launch in anticipation of a possible brenso PDUFA on 2025/08/12, the analyst added.
Overall, Germino told readers that Truist Securities "remain buyers into Insmed's inflection points in 2025."
Earnings Report
Insmed reported:
For Q4 2024:
- Loss per share of $1.32, which missed the Zacks Consensus Estimate of $(1.15) and, by 3.1%, Q4 2023’s $(1.28).
- Revenue of $104.44M, which beat the Zacks Consensus Estimate by 0.10% and, by 24.8%, Q4 2023’s $83.69M.
For FY 2024:
- Loss of $5.57, compared to FY 2023’s loss of $5.34.
- Revenue of $363.7M, up 19.2% Y/Y.
Management did not provide EPS and revenue guidance in its press release.
Chairman & CEO Will Lewis commented: "As we report on the most important year in Insmed's history, we feel we are in a rare position in our industry, with extraordinary opportunities ahead.
“Our success across all areas of the business in 2024—most notably the delivery of positive data from the landmark Phase 3 ASPEN study of brensocatib in bronchiectasis—has positioned us to potentially reach many more patients suffering from serious diseases, and resulted in significant value creation.
"In 2025, we look forward to delivering the highly anticipated U.S. launch of brensocatib, pending FDA approval, and we are delighted to be one step closer to achieving that goal with the FDA's acceptance of our NDA with Priority Review.
“Simultaneously, we expect to continue to advance our robust mid- to late-stage pipeline while generating double-digit worldwide revenue growth for ARIKAYCE.
“We believe that Insmed's strong balance sheet and unique company culture will enable us to deliver on behalf of patients in need."
Stephen Willey, a bottom 4% analyst from Stifel Nicolaus maintains INSM with a strong buy rating and lowers their INSM price target from $97.00 to $96.00, on Feb 21, 2025.
Tiago Fauth, a bottom 4% analyst from Wells Fargo maintains INSM with a strong buy rating and raises their INSM price target from $85.00 to $107.00, on Feb 19, 2025.
Jessica Fye, a top 5% analyst from JP Morgan maintains INSM with a strong buy rating and raises their INSM price target from $83.00 to $92.00, on Feb 7, 2025.
Matthew Harrison, a top 29% analyst from Morgan Stanley maintains INSM with a strong buy rating and raises their INSM price target from $85.00 to $90.00, on Feb 6, 2025.
You can dive deeper into what analysts are saying on the Insmed stock forecast page.
INSM Technical Indicators
INSM Growth Metrics
Last year, INSM revenue was $363.71M. During the past 5 year, INSM's revenue has gone up by 21.66% per year. This was slower than the Biotechnology industry average of 45.66%.
Dig into INSM's earnings and revenue performance here.
Who is buying/selling INSM?
In the last year, insiders at INSM have sold more shares than they have bought.
William Lewis, Chair and CEO of INSM, was the latest INSM insider to buy. They bought $74,105.50 worth of INSM shares on Apr 15, 2025.
Research more about who owns INSM stock here.
Does INSM stock generate passive income?
No, Insmed doesn't provide an income stream by paying out dividends.
What do other investors have to say about INSM?
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Place your INSM buy order
There are two main order types:
- Market order: A market order is an order to buy or sell a security at the best price on the market.
Market orders are mostly the easiest way to buy. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be certain you're buying or selling at a particular dollar amount, place a limit order.
Hit the Open Trade button and your broker will place your order.
If you require more help with buying stocks on eToro, click the helpful video below:
Step 6: Get updates on your investment in INSM
Now that you own some INSM shares, you'll want to stay up-to-date on your shares.
Add INSM to a watchlist to keep tabs on your INSM stock.
INSM Feed
How to Buy Stock in Insmed
To reiterate, here are the 6 steps you need to take to buy Insmed stock right now:
- Figure out where to buy Insmed stock
- Sign up for your brokerage account
- Deposit funds into your brokerage account
- Analyze Insmed stock
- Place your INSM buy order
- Get updates on your investment in INSM
If you require a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to get notifications regarding your investment in Insmed, create your watchlist below.
Related Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.